Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Omadacycline is a Potential New Drug For Treatment in Moderate to Severe Community-acquired Pneumonia

Zappetti, Dana MD

Clinical Pulmonary Medicine: July 2019 - Volume 26 - Issue 4 - p 135
doi: 10.1097/CPM.0000000000000316
Pulmonary Trends

Synopsis: Omadacycline is a new antibiotic, derived from the tetracycline class, which might fill the need for a novel antibiotic that is effective against the common bacterial organisms causing community-acquired pneumonia. This trial showed it to be noninferior to moxifloxacin.

Source: Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380:517–527.

Disclosure: The author declares that there is no conflicts of interest.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.